Accelerate Diagnostics Stock Analysis (NASDAQ:AXDX)

Add to My Stocks
$26.95 $0.35 (1.32%) AXDX stock closing price Feb 27, 2017 (Closing)
Watch Robo Advisor Video of AXDX Stock Analysis
Accelerate Diagnostics
Updated on : Feb 27, 2017
previous close
AXDX 27 (0%)
S&P 500 2369.8 (0%)
Closing Price On: Feb 27, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical Instruments
Sector :
5 Quarter Revenue
Revenue Growth
Compared to the industry
Long Term Growth
5 Year CAGR:
Operating Profit
Operating Margin:
Sector Average:
5 Quarter Net Profit
Net Margins
LTM Margin
Cash Flow
Operating cash flow:
Net Income:
Long Term Growth
Operating Margins
Net Margins
FCF Margin
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
Industry PS :
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
Return on Equity:
Free Cash Flow Margin:
Double Tap To Exit Full Screen

Accelerate Diagnostics Analysis Video

127 5 2

View Accelerate Diagnostics stock analysis video. This is our AXDX analyst opinion covering the buy and sell arguments for AXDX stock.

Accelerate Diagnostics Inc Stock Rating (1.9/5)

Our Accelerate Diagnostics stock opinion is based on fundamentals of the company. This Accelerate Diagnostics stock analysis is based on latest Q3 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy AXDX stock?

Should you sell AXDX stock?

  • The company saw an average annual sales decline of in sales over the last 5 years.
  • Over the last twelve months, Accelerate Diagnostics posted an average operating loss margin of -28631.8%.
  • Accelerate Diagnostics registered an average TTM Net loss of -28818.2%.
  • The company does not have profits. Hence the PE ratio is meaningless for AXDX stock.
  • The company is trading at a price to sales multiple of 6276.9, which is overvalued in comparison to the Medical Instruments industry average multiple of 4.7.
  • The company has a negative Return on Invested Capital of -2402.8%, which is a red flag.
  • Accelerate Diagnostics has a negative ROE (Return On Equity) of -64.8%, indicating the company is not profitable.
  • The company has negative Free Cash Flows (FCF), with a negative FCF margin of -63700%.

Comments on this video and Accelerate Diagnostics stock